Nanoparticle-in-Microparticle Oral Delivery System Based on Drug-Loaded Polymeric Micelles

This study presents a hierarchical oral drug delivery system featuring drug-loaded polymeric nanogels encapsulated within a mucoadhesive alginate/chitosan microparticle shell, which demonstrates controlled release and a significantly extended oral half-life compared to the free drug.

The Gist

Imagine you are trying to deliver a precious, fragile package (a medicine called Dasatinib) to a specific destination inside your body: the bloodstream. However, the journey is a nightmare. The medicine has to travel through a "tropical storm" (your stomach acid) and then navigate a "fast-moving river" (your intestines) where it gets washed away before it can do its job. Furthermore, the medicine itself is like oil in water—it doesn't mix well with the fluids in your body, making it hard to absorb.

This paper describes a clever, two-layered "Trojan Horse" strategy designed to solve these problems. The scientists built a hierarchical delivery system, which is just a fancy way of saying they created a "package within a package."

Here is how it works, broken down into simple analogies:

1. The Inner Package: The "Smart Sponge" (Nanogels)

First, the scientists took the medicine and hid it inside tiny, microscopic sponges made of special polymers. Think of these as smart sponges that are designed to hold onto the medicine tightly.

• Why? These sponges protect the medicine from dissolving too quickly.
• The Problem: If you just swallow these tiny sponges, they are so small that they zoom through your intestines too fast, or the stomach acid might break them open before they reach the right spot.

2. The Outer Shell: The "Mucoadhesive Bubble" (Microparticles)

To fix the "zooming away" problem, the scientists put thousands of those tiny sponges inside a larger, sticky bubble made of natural materials (alginate and chitosan, which are like seaweed and shrimp shells).

• The Analogy: Imagine the tiny sponges are seeds, and the outer bubble is a sticky piece of Velcro.
• The Magic: When you swallow this larger bubble, the "Velcro" side sticks to the lining of your gut (the mucosa). Instead of rushing through the digestive tract, the bubble parks itself there. This gives the tiny sponges inside plenty of time to slowly release the medicine right where it's needed.

3. The Armor: The "Raincoat" (Film Coating)

The scientists added one final layer: a special plastic coating (like a raincoat) around the sticky bubble.

• The Function: This raincoat is designed to be acid-proof. It stays solid in the stomach (the acid storm) so the medicine doesn't get destroyed.
• The Release: Once the bubble reaches the intestines (where the environment is less acidic), the raincoat dissolves. This reveals the sticky "Velcro" bubble, which then sticks to the gut wall and starts the slow, steady release of the medicine.

What Did They Find? (The Results)

The scientists tested this system on rats and compared it to just swallowing the raw medicine or the raw sponges without the sticky bubble.

• The Raw Medicine: It acted like a sprinter. It entered the blood very fast (a high peak), but then disappeared quickly. This is bad because it can cause side effects (toxicity) and doesn't last long enough to be effective.
• The Sponges Alone: They slowed things down a bit, but the medicine still didn't stay in the body long enough.
• The "Package-in-Package" System (NiMODS): This was the winner.
  • Slower Peak: Instead of a sudden, dangerous spike of medicine in the blood, it released a gentle, steady stream. This is safer for the body.
  • Longer Stay: The most impressive result was that the medicine stayed in the rats' systems 10 times longer than the raw drug! (The "half-life" went from about 7 hours to nearly 3 days).
  • Same Total Effect: Even though it was released slowly, the total amount of medicine the body absorbed was just as good as the raw drug, but without the dangerous spikes.

The Bottom Line

This research shows that by nesting tiny drug carriers inside a larger, sticky, acid-proof shell, we can turn a medicine that is usually hard to swallow into a highly effective, long-lasting treatment. It's like upgrading from a paper boat that sinks in a storm to a submarine that can dive deep, stick to the ocean floor, and release its cargo exactly where it's needed.

This "Nanoparticle-in-Microparticle" system could be a game-changer for delivering difficult drugs, making them safer and more effective for patients.

Technical Summary

1. Problem Statement

The pharmaceutical industry faces significant challenges with hydrophobic drugs, which constitute 50–70% of market drugs. These compounds suffer from:

• Poor aqueous solubility and permeability: Leading to limited absorption in the gastrointestinal (GI) tract and low oral bioavailability.
• Short residence time: Conventional formulations pass through the GI tract too quickly for effective absorption.
• Instability: Harsh gastric conditions can degrade drug payloads before intestinal absorption occurs.
• Limitations of existing nanocarriers: While polymeric micelles (nanoparticles) improve solubility, they often exhibit "burst release" and lack the stability required for sustained oral delivery.

2. Methodology

The authors developed a hierarchical Nanoparticle-in-Microparticle Oral Delivery System (NiMODS) designed to combine the solubility benefits of nanoparticles with the mucoadhesive and protective properties of microparticles.

• Core Nanoparticles (Nanogels):
  • Material: Amphiphilic nanogels made of a poly(vinyl alcohol)-poly(methyl methacrylate) (PVA-g-PMMA) graft copolymer.
  • Drug: Loaded with Dasatinib (a tyrosine kinase inhibitor) at 10% w/w.
  • Crosslinking: Boric acid crosslinking.
  • Fabrication: Produced via a one-step process in a Y-shape microfluidics device.
• Microparticle Encapsulation:
  • Matrix: The drug-loaded nanogels were spray-dried and re-dispersed in a solution of alginate and chitosan (both FDA "Generally Recognized As Safe" polysaccharides).
  • Formation: Microencapsulated using ionotropic crosslinking with calcium cations.
  • Size: Resulting microparticles were ~1.5 µm (uncoated) to 30–50 µm (coated).
• Gastro-Resistance Coating (Double Film-Coating):
  • Layer 1 (Inner): Eudragit® RL PO (water-insoluble, swells to become permeable, designed for sustained release).
  • Layer 2 (Outer): Eudragit® S100 (insoluble at acidic pH, dissolves at intestinal pH > 7.0).
  • Rationale: The outer layer protects the system in the stomach; upon reaching the intestine, it dissolves to expose the inner permeable layer, controlling release.
• Evaluation Models:
  • In Vitro: Caco-2 and HT29-MTX cell lines (intestinal epithelium model) for cytotoxicity and permeability ($P_{app}$). Release kinetics tested at pH 1.2 (stomach) and pH 6.8 (intestine).
  • In Vivo: Oral administration in Sprague-Dawley rats ($n=6$) to assess pharmacokinetics (PK).

3. Key Contributions

• Hierarchical Design: Successfully integrated drug-loaded nanogels into a mucoadhesive microparticle shell, creating a "Nanoparticle-in-Microparticle" architecture.
• Dual-Stage Coating Strategy: Implemented a specific double-coating mechanism to ensure gastric resistance followed by controlled, sustained release in the intestine.
• Overcoming Loading Limitations: Addressed the low drug loading (1.1% w/w) of the final formulation by optimizing the dosing strategy in animal models to demonstrate efficacy despite the low payload.
• Biocompatibility Validation: Confirmed that all components, including the boric acid crosslinker, are non-toxic to intestinal cell lines.

4. Key Results

A. Physicochemical Characterization

• Nanogels: Freshly prepared nanogels had a hydrodynamic diameter of ~149 nm (intensity) and ~63 nm (number). After spray-drying and re-dispersion, sizes were ~129 nm and ~54 nm, confirming excellent redispersibility and network consolidation.
• Microparticles: Final NiMODS particles were spherical with smooth surfaces. The final dasatinib loading was 1.1% w/w.

B. Biocompatibility & Permeability

• Cytotoxicity: Cell viability in Caco-2 and HT29-MTX lines remained >78% after 4–72 hours of exposure, well above the ISO 10993-5 toxicity limit (70%).
• Permeability: The apparent permeability ($P_{app}$) of non-loaded nanogels was 32.6 ± 3.2 × 10⁻⁷ cm/s, indicating good transport potential across the intestinal epithelium.

C. In Vitro Release Kinetics

• Nanogels vs. Free Drug: Nanogels slowed release compared to free dasatinib (e.g., at pH 1.2, 42% release vs. 66% for free drug after 4 hours).
• NiMODS vs. Nanogels: The double-coated NiMODS exhibited the most sustained release. At pH 6.8, only 16% of the drug was released after 4 hours, significantly lower than free drug or uncoated nanogels. The release profile best fit the Weibull model.

D. In Vivo Pharmacokinetics (Rats)

• 10 mg/kg Dose (Nanogels only):
  • Compared to free drug, nanogels showed a drastically lower $C_{max}$ (13.8 vs. 86.4 ng/mL) and a significantly prolonged half-life ($t_{1/2}$: 19.4 h vs. 3.8 h).
  • Drawback: The Area Under the Curve ($AUC_{0-\infty}$) dropped significantly (168.9 vs. 604.2 ng/mL/h), suggesting reduced overall bioavailability at this high dose due to rapid clearance or poor absorption of the uncoated nanogels.
• 5 mg/kg Dose (NiMODS vs. Free Drug):
  • $C_{max}$: Reduced from 63.3 ng/mL (free) to 14.6 ng/mL (NiMODS), indicating a smoother, less toxic peak.
  • $t_{1/2}$: Dramatically extended from 6.7 h to 67.2 h.
  • $AUC_{0-\infty}$: Remained statistically identical between free drug and NiMODS (370.0 vs. 366.3 µg/mL/h).
  • Efficiency: The 5 mg/kg NiMODS dose yielded a 2.2-fold increase in AUC compared to the 10 mg/kg nanogel dose, proving the critical role of the mucoadhesive microparticle in retaining the nanogels in the gut.

5. Significance

This study demonstrates a successful strategy to overcome the limitations of oral delivery for hydrophobic drugs by integrating two distinct delivery mechanisms:

1. Nanoparticles to solubilize the drug and facilitate permeation.
2. Mucoadhesive Microparticles to prolong GI residence time and prevent burst release.

The NiMODS system achieved a "best of both worlds" scenario: it maintained therapeutic bioavailability (AUC) comparable to the free drug while significantly extending the half-life and reducing the peak plasma concentration ($C_{max}$). This reduction in $C_{max}$ is clinically significant as it suggests a potential reduction in off-target systemic toxicity, while the prolonged half-life ensures sustained therapeutic efficacy. The work provides a scalable platform for the oral administration of a broad spectrum of small-molecule and biological drugs.